Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Accounts Payables: 2015-2024

Historic Accounts Payables for Seres Therapeutics (MCRB) over the last 10 years, with Dec 2024 value amounting to $4.1 million.

  • Seres Therapeutics' Accounts Payables fell 79.68% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 79.68%. This contributed to the annual value of $4.1 million for FY2024, which is 12.03% up from last year.
  • Per Seres Therapeutics' latest filing, its Accounts Payables stood at $4.1 million for FY2024, which was up 12.03% from $3.6 million recorded in FY2023.
  • Seres Therapeutics' 5-year Accounts Payables high stood at $17.4 million for FY2022, and its period low was $3.6 million during FY2023.
  • Moreover, its 3-year median value for Accounts Payables was $4.1 million (2024), whereas its average is $8.4 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first surged by 241.84% in 2021, then plummeted by 79.12% in 2023.
  • Seres Therapeutics' Accounts Payables (Yearly) stood at $4.0 million in 2020, then surged by 241.84% to $13.7 million in 2021, then increased by 26.97% to $17.4 million in 2022, then tumbled by 79.12% to $3.6 million in 2023, then grew by 12.03% to $4.1 million in 2024.